menu
    • menu

    Company profile for Inflammasome Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Inflammasome Therapeutics is a science-based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration and type 2 diabetes. The precise causes of these diseases are unknown; however they share many of the same risk factors – smoking, obesity, hypertension, and age. They all are multifactorial diseases with multiple biochemical factors, m...
    Inflammasome Therapeutics is a science-based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration and type 2 diabetes. The precise causes of these diseases are unknown; however they share many of the same risk factors – smoking, obesity, hypertension, and age. They all are multifactorial diseases with multiple biochemical factors, many shared, contributing to their progression.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Inflammasome TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    57 Chapel Street Suite 100 Newton, MA 02458
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.inflam.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inflammasome Therapeutics Completes Ph II Study Enrollment
    Inflammasome Therapeutics Completes Ph II Study Enrollment

    25 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125986655/en/Inflammasome-Therapeutics-Completes-Enrollment-of-Multicenter-Phase-II-Dose--Ranging-Study-for-First-in-Class-Dual-Inflammasome-Inhibitor-K8-to-Treat-Geographic-Atrophy

    BUSINESSWIRE
    25 Nov 2025
    Share Share
    Inflammasome, Healey Center Partner on New ALS Treatment
    Inflammasome, Healey Center Partner on New ALS Treatment

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113753626/en/Inflammasome-Therapeutics-to-Collaborate-with-Sean-M.-Healey-AMG-Center-for-ALS-on-a-new-treatment-for-Amyotrophic-Lateral-Sclerosis-ALS

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    Inflammasome's K8 Implant Cuts Lesion Growth 50% in Atrophy Trial
    Inflammasome's K8 Implant Cuts Lesion Growth 50% in Atrophy Trial

    11 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250911932452/en/Inflammasome-Therapeutics-K8-Implant-Cuts-Lesion-Growth-by-more-than-50-in-Geographic-Atrophy-after-Three-Months-in-Multi-Center-Trial

    BUSINESSWIRE
    11 Sep 2025
    Share Share
    Inflammasome Reports Success In Eye Treatment Clinical Trial
    Inflammasome Reports Success In Eye Treatment Clinical Trial

    15 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250115779420/en

    BUSINESSWIRE
    15 Jan 2025
    Share Share
    Halia To Present HT-6184 Phase II Data At Inflammasome Summit
    Halia To Present HT-6184 Phase II Data At Inflammasome Summit

    10 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-to-present-an-update-on-phase-ii-clinical-trial-data-of-ht-6184-at-the-6th-inflammasome-therapeutics-summit-302242860.html

    PR NEWSWIRE
    10 Sep 2024
    Share Share
    Inflammasome Completes Enrollment For Dual Inhibitor Study
    Inflammasome Completes Enrollment For Dual Inhibitor Study

    10 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240910093529/en

    BUSINESSWIRE
    10 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search